Y Intercept Hong Kong Ltd Invests $33,000 in Perspective Therapeutics, Inc. (NYSE:CATX)

Y Intercept Hong Kong Ltd acquired a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 10,263 shares of the company’s stock, valued at approximately $33,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. FMR LLC grew its stake in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Janus Henderson Group PLC grew its stake in Perspective Therapeutics by 8.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after buying an additional 355,685 shares during the last quarter. State Street Corp grew its stake in Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the last quarter. Nicholson Wealth Management Group LLC grew its position in shares of Perspective Therapeutics by 0.4% during the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock worth $5,134,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Perspective Therapeutics by 12.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock worth $15,546,000 after purchasing an additional 129,654 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Stock Up 7.7 %

Shares of Perspective Therapeutics stock opened at $2.53 on Thursday. The company has a 50 day moving average of $3.23 and a 200-day moving average of $7.87. Perspective Therapeutics, Inc. has a 1-year low of $2.32 and a 1-year high of $19.05.

Analyst Ratings Changes

A number of research analysts have issued reports on CATX shares. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 22nd. Royal Bank of Canada restated an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.